Stock listing
BOATS:SNGX Soligenix, Inc. Stock
US listing (BOATS) of Soligenix, Inc. · home listing NASDAQ:SNGX
Follow Soligenix, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SNGX
$0.22 USD -0.03 (-12.9%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SNGX
- Day range
- $0.212 – $0.24 USDNov 20, 2026
- Volume
- 330,314 sharesNov 20, 2026
- Market cap
- $5.14M USDAt the close on Nov 20, 2026 · price × 23.37M shares outstanding
- 52-week range
- $0.212 – $1.70 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $74,304 USDMedian day 131,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SNGX · Home | $0.22 USD | -0.033 (-12.9%) | 330,314 | $0.24 | $0.24 | $0.212 | $0.253 | Close on Nov 20, 2026 |
| LSE:0A6I | $0.225 USD | -0.023 (-9.4%) | 21,133 | $0.235 | $0.238 | $0.214 | $0.248 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SNGX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.22 | -0.033 | -12.9% | $0.24 | $0.24 | $0.212 | 330,314 | |
| $0.253 | -0.028 | -9.9% | $0.28 | $0.281 | $0.231 | 544,838 | |
| $0.281 | -0.008 | -2.7% | $0.288 | $0.295 | $0.276 | 258,161 | |
| $0.288 | -0.033 | -10.2% | $0.315 | $0.315 | $0.269 | 693,619 | |
| $0.321 | +0.001 | +0.3% | $0.317 | $0.323 | $0.312 | 135,555 | |
| $0.32 | -0.001 | -0.4% | $0.314 | $0.34 | $0.31 | 203,049 | |
| $0.321 | +0.001 | +0.4% | $0.32 | $0.325 | $0.316 | 62,120 | |
| $0.32 | -0.022 | -6.3% | $0.332 | $0.35 | $0.314 | 298,954 | |
| $0.342 | +0.007 | +2.0% | $0.35 | $0.355 | $0.34 | 130,787 | |
| $0.335 | +0.002 | +0.5% | $0.33 | $0.348 | $0.33 | 106,852 | |
| $0.333 | -0.018 | -5.0% | $0.351 | $0.355 | $0.333 | 138,383 | |
| $0.351 | -0.005 | -1.5% | $0.362 | $0.364 | $0.351 | 76,181 | |
| $0.356 | -0.005 | -1.4% | $0.36 | $0.365 | $0.356 | 114,736 | |
| $0.361 | +0.005 | +1.5% | $0.368 | $0.37 | $0.355 | 137,408 | |
| $0.356 | -0.013 | -3.6% | $0.378 | $0.378 | $0.355 | 69,423 | |
| $0.369 | -0.006 | -1.5% | $0.376 | $0.378 | $0.368 | 36,555 | |
| $0.375 | +0.012 | +3.3% | $0.351 | $0.375 | $0.351 | 62,279 | |
| $0.363 | +0.013 | +3.7% | $0.35 | $0.37 | $0.35 | 74,407 | |
| $0.35 | -0.02 | -5.4% | $0.369 | $0.371 | $0.35 | 47,606 | |
| $0.37 | +0.01 | +2.8% | $0.35 | $0.37 | $0.34 | 127,000 | |
| $0.36 | +0.01 | +2.9% | $0.37 | $0.37 | $0.35 | 131,600 | |
| $0.35 | 0.00 | 0.0% | $0.34 | $0.37 | $0.34 | 69,100 | |
| $0.35 | +0.01 | +2.9% | $0.34 | $0.36 | $0.34 | 81,200 | |
| $0.34 | -0.01 | -2.9% | $0.34 | $0.35 | $0.34 | 69,700 | |
| $0.35 | -0.01 | -2.8% | $0.36 | $0.36 | $0.35 | 217,700 | |
| $0.36 | +0.02 | +5.9% | $0.34 | $0.36 | $0.34 | 163,200 | |
| $0.34 | +0.01 | +3.0% | $0.32 | $0.35 | $0.32 | 148,200 | |
| $0.33 | -0.02 | -5.7% | $0.35 | $0.37 | $0.33 | 267,400 | |
| $0.35 | -0.01 | -2.8% | $0.36 | $0.37 | $0.35 | 61,800 | |
| $0.36 | +0.01 | +2.9% | $0.35 | $0.37 | $0.35 | 114,500 | |
| $0.35 | 0.00 | 0.0% | $0.36 | $0.36 | $0.35 | 120,200 | |
| $0.35 | -0.01 | -2.8% | $0.36 | $0.36 | $0.35 | 62,800 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.36 | $0.36 | 185,600 | |
| $0.36 | -0.01 | -2.7% | $0.36 | $0.37 | $0.36 | 107,900 | |
| $0.37 | +0.01 | +2.8% | $0.37 | $0.37 | $0.36 | 146,500 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.37 | $0.36 | 45,300 | |
| $0.36 | -0.01 | -2.7% | $0.37 | $0.37 | $0.36 | 90,300 | |
| $0.37 | -0.01 | -2.6% | $0.38 | $0.38 | $0.36 | 406,600 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.38 | $0.38 | 135,000 | |
| $0.38 | -0.01 | -2.6% | $0.39 | $0.39 | $0.38 | 72,700 | |
| $0.39 | 0.00 | 0.0% | $0.38 | $0.39 | $0.38 | 228,600 | |
| $0.39 | 0.00 | 0.0% | $0.39 | $0.39 | $0.38 | 372,700 | |
| $0.39 | +0.02 | +5.4% | $0.39 | $0.39 | $0.38 | 529,800 | |
| $0.37 | 0.00 | 0.0% | $0.38 | $0.38 | $0.37 | 341,300 | |
| $0.37 | -0.01 | -2.6% | $0.37 | $0.39 | $0.37 | 257,400 | |
| $0.38 | +0.02 | +5.6% | $0.36 | $0.40 | $0.36 | 971,500 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.36 | $0.36 | 125,800 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.37 | $0.36 | 288,300 | |
| $0.36 | 0.00 | 0.0% | $0.37 | $0.37 | $0.36 | 98,400 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.37 | $0.36 | 147,200 | |
| $0.36 | -0.01 | -2.7% | $0.36 | $0.37 | $0.36 | 124,100 | |
| $0.37 | -0.01 | -2.6% | $0.38 | $0.39 | $0.37 | 126,400 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.38 | 95,200 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.38 | $0.38 | 119,100 | |
| $0.38 | 0.00 | 0.0% | $0.39 | $0.39 | $0.38 | 59,900 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.37 | 90,000 | |
| $0.38 | 0.00 | 0.0% | $0.37 | $0.39 | $0.37 | 122,200 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.36 | 400,300 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.37 | 139,500 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.38 | 379,200 | |
| $0.38 | -0.03 | -7.3% | $0.40 | $0.40 | $0.38 | 590,900 | |
| $0.41 | +0.01 | +2.5% | $0.41 | $0.41 | $0.40 | 218,100 | |
| $0.40 | 0.00 | 0.0% | $0.41 | $0.41 | $0.40 | 311,100 | |
| $0.40 | +0.02 | +5.3% | $0.38 | $0.42 | $0.38 | 989,200 | |
| $0.38 | 0.00 | 0.0% | $0.38 | $0.39 | $0.38 | 94,000 |
Splits
5 splits since 1997 · NASDAQ:SNGX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-16 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-15 | Consolidation |
- Ticker
- BOATS:SNGX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 6, 2026
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
Latest deck · Apr 8, 2026
Investor Presentation (April 2026)
Investor deck · 26 slides
Latest news
Soligenix Announces Recent Updates and Third Quarter 2026 Financial Results
Nov 6, 2026
Closed $0.335 (+0.5%) on Nov 6, 2026
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Jun 8, 2026
Closed $0.42 (-4.5%) on Jun 8, 2026
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026
Closed $0.51 (+30.8%) on May 26, 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026
Closed $0.29 (-6.5%) on May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Apr 28, 2026
Closed $0.42 (-70.4%) on Apr 28, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Apr 2, 2026
Closed $1.14 (-0.9%) on Apr 2, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Mar 31, 2026
Closed $1.18 (+6.3%) on Mar 31, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Mar 26, 2026
Closed $1.21 (+0.8%) on Mar 26, 2026
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Mar 24, 2026
Closed $1.17 (-3.3%) on Mar 24, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Mar 23, 2026
Closed $1.21 (+0.8%) on Mar 23, 2026
Soligenix, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 19 in the last 12 months · 192 in all · newest Nov 6, 2026 · oldest 2019
- Decks
- 49 decks · latest Apr 8, 2026
Where Soligenix, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SNGX · Home listing | NASDAQ | United States | USD |
| BOATS:SNGX · This page | BOATS | United States | USD |
| gettex:DOA0 | gettex | Germany | EUR |
| LSE:0A6I | LSE | United Kingdom | USD |
| Munich:DOA0 | Munich | Germany | EUR |
Valuation
Price/book 0.8× against a median of 1.2×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$3.61M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.76
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Soligenix, Inc. · NASDAQ:SNGX | US$5.14M | −US$3.61M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.76 |
| Hemostemix Inc · TSXV:HEM | US$5.35M | US$7.70M | n/a | n/a | n/a | n/a | n/a | n/a | 0.47 |
| Curative Biotechnology Inc · OTC:CUBT | US$5.34M | US$6.55M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| Abpro Holdings, Inc. · OTC:ABPO | US$5.31M | US$1.07M | 2.6× | n/a | n/a | n/a | n/a | n/a | -0.79 |
| CNS Pharmaceuticals, Inc. · NASDAQ:CNSP | US$5.25M | −US$11.96M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.74 |
| Rakovina Therapeutics Inc · TSXV:RKV | US$5.10M | US$7.20M | n/a | n/a | n/a | n/a | n/a | n/a | -0.43 |
| StimCell Energetics Inc. · OTC:STME | US$5.10M | US$5.09M | n/a | n/a | n/a | n/a | n/a | n/a | 0.99 |
| Longeveron Inc. · NASDAQ:LGVN | US$5.05M | −US$1.78M | n/a | −1.5× | n/a | 1.1× | n/a | 0.1× | 1.55 |
| Oncodesign Precision Medicine S.A. · EURONEXT:ALOPM | US$5.04M | US$8.61M | 0.8× | 30.0× | 0.9× | 1.2× | n/a | 1.6× | n/a |
| Patrys Limited · ASX:PAB | US$4.96M | US$4.47M | n/a | 8.2× | n/a | 10.2× | −363.7% | 0.0× | n/a |
| Invex Therapeutics Ltd. · ASX:IXC | US$4.86M | US$2.20M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Median of the others | US$5.10M | US$4.78M | 1.7× | 8.2× | 0.9× | 1.2× | −363.7% | 0.0× | 0.74 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.38 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.40 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher J. Schaber | Chairman, President and Chief Executive Officer |
| Jonathan L. Guarino | Senior Vice President and Chief Financial Officer |
| Adam T. Rumage | Senior Vice President, Project Management & Regulatory Affairs |
| Oreola Donini | Senior Vice President and Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Christopher J. Schaber | Chairman, President and Chief Executive Officer |
| Diane L. Parks | Board Director |
| Gregg A. Lapointe | Board Director |
| Jerome Zeldis | Board Director |
| Robert J. Rubin | Board Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · After close | +2.0% |
| Q2 2026 | Aug 7, 2026 | 0.0% |
| Q1 2026 | May 8, 2026 · After close | −3.5% |
| Q3 2025 | Nov 7, 2025 · After close | −0.7% |
| Q2 2025 | Aug 14, 2025 · After close | −5.4% |
| Q1 2025 | May 9, 2025 · After close | −1.0% |
| Q4 2024 | Mar 13, 2025 · Before open | −0.9% |
| Q3 2024 | Nov 8, 2024 · After close | +2.6% |
| Q2 2024 | Aug 9, 2024 · After close | −1.6% |
| Q1 2024 | May 10, 2024 · After close | −2.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 15, 2024 · After close | −1.6% |
| Q3 2023 | Nov 13, 2023 · After close | −2.4% |
| Q2 2023 | Aug 21, 2023 · Before open | +2.2% |
| Q1 2023 | May 15, 2023 · Before open | +6.4% |
| Q4 2022 | Mar 31, 2023 · Before open | −3.9% |
| Q3 2022 | Nov 10, 2022 · After close | +4.5% |
| Q2 2022 | Aug 12, 2022 · After close | −2.3% |
| Q1 2022 | May 13, 2022 · After close | +5.0% |
| Q4 2021 | Mar 29, 2022 · Before open | +1.4% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 26 slides | Apr 8, 2026 |
| Investor Presentation (January 2026) | Investor deck | 26 slides | Jan 8, 2026 |
| Investor Presentation (November 2025) | Investor deck | 26 slides | Nov 24, 2025 |
| Investor Presentation (September 2025) | Investor deck | 26 slides | Sep 19, 2025 |
| Investor Presentation (August 2025) | Investor deck | 26 slides | Aug 22, 2025 |
| Investor Presentation (May 2025) | Investor deck | 24 slides | May 1, 2025 |
| Investor Presentation (March 2025) | Investor deck | 24 slides | Mar 6, 2025 |
| Investor Presentation (January 2025) | Investor deck | 24 slides | Jan 14, 2025 |
| Investor Presentation (October 2024) | Investor deck | 24 slides | Oct 3, 2024 |
| Investor Presentation (June 2024) | Investor deck | 24 slides | Jun 10, 2024 |
All 49 decks
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or common stock equivalents) and warrants Closed: US$7.5M raised · US$1.35 a share · Warrants at US$1.35 for 60 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Research and development and commercialization activities, working capital and general corporate purposes | Sep 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 119.4K | 839.4K | 948.9K | 824.3K | 2.36M | 4.63M | 5.24M | 5.43M | 10.4M |
| Cost of revenue | 0 | 119.4K | 742.0K | 550.8K | 728.6K | 1.82M | 3.57M | 4.60M | 4.31M | 8.43M |
| Gross profit | 0 | -119.4K | 97.3K | 398.1K | 95.6K | 538.5K | 1.06M | 643.7K | 1.12M | 2.02M |
| Research and development | 7.49M | 5.22M | 3.31M | 7.94M | 8.19M | 9.80M | 8.12M | 6.75M | 5.51M | 4.30M |
| Selling, general and administrative | 4.36M | 4.22M | 4.48M | 6.69M | 5.01M | 4.33M | 3.48M | 2.95M | 3.21M | 3.43M |
| Operating income | -11.8M | -9.44M | -7.70M | -14.2M | -13.1M | -18.6M | -10.5M | -9.06M | -7.59M | -5.71M |
| Depreciation and amortization | 3.22K | 5.81K | 6.55K | 24.6K | 34.2K | 62.4K | 54.5K | 44.1K | 68.6K | 89.9K |
| EBITDA | -11.8M | -9.43M | -7.69M | -14.2M | -13.1M | -18.5M | -10.5M | -9.01M | -7.53M | -5.62M |
| Interest expense | 214.0K | 49.1K | 822.6K | 904.5K | 34.3K | 133.3K | 0 | 0 | 0 | |
| Income before tax | -11.6M | -8.68M | -7.91M | -15.0M | -13.4M | -18.5M | -9.97M | -8.90M | -7.56M | -3.78M |
| Income tax | -506.6K | -409.1K | -1.77M | -1.15M | -864.7K | -836.9K | -610.7K | 159.0K | -416.8K | -530.1K |
| Net income | -11.1M | -8.27M | -6.14M | -13.8M | -12.6M | -17.7M | -9.36M | -8.90M | -7.15M | -3.25M |
| Earnings per share, basic | -2.14 | -4.98 | -12.66 | -4.81 | -4.69 | -0.64 | -0.48 | -0.68 | -1.16 | -0.93 |
| Earnings per share, diluted | -2.14 | -4.98 | -12.66 | -4.81 | -4.69 | -0.64 | -0.48 | -0.68 | -1.16 | -1.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.94M | 7.82M | 8.45M | 13.4M | 26.0M | 18.7M | 5.42M | 8.98M | 7.81M | 8.77M |
| Short-term investments | 0 | 0 | ||||||||
| Receivables | 195.1K | 219.3K | 242.7K | 564.9K | 1.46M | 1.20M | 1.34M | 1.21M | ||
| Inventory | 1 | 1 | 2 | 1 | 1 | 1 | ||||
| Current assets | 8.85M | 8.83M | 9.51M | 13.9M | 26.6M | 19.5M | 7.49M | 10.3M | 9.42M | 10.1M |
| Property, plant and equipment | 8.77K | 6.11K | 11.9K | 18.5K | 22.2K | 23.5K | 36.1K | 19.6K | 37.2K | 26.7K |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 9.24M | 8.97M | 9.80M | 14.3M | 26.9M | 19.9M | 7.78M | 10.5M | 9.55M | 10.3M |
| Accounts payable | 1.12M | 667.9K | 1.11M | 3.87M | 2.93M | 2.13M | 2.74M | 2.13M | 1.75M | 1.71M |
| Current liabilities | 3.70M | 4.85M | 6.15M | 16.5M | 6.29M | 6.08M | 6.31M | 4.21M | 3.23M | 2.87M |
| Long-term debt | 1.01M | 9.86M | 9.95M | 6.15K | 0 | 0 | ||||
| Total debt | 358.1K | 0 | 1.01M | 0 | 9.96M | 10.5M | 127.2K | |||
| Total liabilities | 3.94M | 4.85M | 7.27M | 16.8M | 16.1M | 16.1M | 6.32M | 4.21M | 3.23M | 2.87M |
| Shareholders' equity | 5.29M | 4.12M | 2.52M | -2.47M | 10.7M | 3.74M | 1.46M | 6.28M | 6.32M | 7.40M |
| Shares outstanding | 10.1M | 2.51M | 648.8K | 2.91M | 2.86M | 30.6M | 21.8M | 17.7M | 8.73M | 5.47M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.3M | -8.40M | -8.60M | -12.6M | -11.7M | -11.5M | -7.51M | -7.24M | -6.51M | -4.98M |
| Capital spending | -5.88K | 0 | -1 | -13.1K | -11.8K | -7.15K | -30.2K | -1.93K | -26.3K | -7.16K |
| Free cash flow | -10.3M | -8.40M | -8.60M | -12.7M | -11.8M | -11.5M | -7.54M | -7.25M | -6.54M | -4.99M |
| Cash from investing | -5.88K | -13.1K | -11.8K | -7.15K | -24.7K | -925 | -26.3K | -7.16K | ||
| Cash from financing | 10.4M | 7.76M | 3.66M | 76.8K | 19.1M | 24.7M | 4.01M | 8.42M | 5.57M | 8.84M |
| Dividends paid | -43 | 0 | 0 | |||||||
| Share buybacks | 4.99K | 4.14M | 8.68M | 6.25M | -809.3K | |||||
| Change in cash | 116.6K | -626.6K | -4.91M | -12.7M | 7.37M | 13.3M | -3.56M | 1.17M | -963.1K | 3.85M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Nov 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 21, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Aug 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 7, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 7, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Aug 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 3, 2026 | Meeting notice | SEC |
| PRER14A | Jul 23, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Jul 21, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 26, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jun 26, 2026 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 25, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 12, 2026 | Management or board change | SEC |
| 8-K · Current report | May 28, 2026 | Current report | SEC |
| 424B5 · Prospectus | May 28, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 8, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 8, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 8, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 3, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 31, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 23, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 18, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 29, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Sep 26, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 19, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 2, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 27, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 18, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 15, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 15, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 15, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 20, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | May 5, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 5, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 28, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 21, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 21, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 21, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 21, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 424B3 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 11, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Aug 16, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 16, 2024 | Current report | SEC |
| 424B3 · Prospectus | Aug 9, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Aug 5, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 29, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 25, 2024 | Material contract | SEC |
| S-1 · Registration statement | Jul 24, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 9, 2024 | Material contract | SEC |
| 8-K · Current report | May 31, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 29, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 28, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 24, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | May 22, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | May 17, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 15, 2024 | Meeting notice | SEC |
| 424B3 · Prospectus | May 10, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2024 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Apr 19, 2024 | Meeting notice | SEC |
| 424B4 · Prospectus | Apr 19, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 3, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 3, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 2, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Mar 15, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 15, 2024 | Annual report | SEC |
| UPLOAD · Letter from the SEC | Jan 19, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jan 12, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 22, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 18, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2023 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Dec 14, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| S-3/A · Registration statement, amended | Dec 8, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 6, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 30, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 20, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 17, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 16, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 13, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 11, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Oct 11, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 22, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 22, 2023 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 15, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 15, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Sep 12, 2023 | Other filings | SEC |
| S-3 · Registration statement | Aug 30, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 21, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2023 | Explanation request | SEC |
| ARS · Annual report to shareholders | Aug 7, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Aug 7, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 7, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jul 7, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 23, 2023 | Current report | SEC |
| 8-K · Current report | May 26, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2023 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | May 8, 2023 | Other filings | SEC |
| 424B4 · Prospectus | May 5, 2023 | Offer document | SEC |
| 4 · Change in ownership | May 5, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 5, 2023 | Insider trade | SEC |
| CORRESP · Letter to the SEC | May 4, 2023 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 4, 2023 | Offer document | SEC |
| 8-K · Current report | May 3, 2023 | Material contract | SEC |
| 8-K · Current report | May 1, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Apr 19, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 19, 2023 | Other filings | SEC |
This page holds 200 of 1,006 filings. Open Filings
Cap table
Built by 6ix from Soligenix, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 23,368,754
- Fully diluted
- 23,368,754
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 23,368,754 | Oct 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.35 · expire about Sep 2030 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 23,368,754 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jerome Zeldis Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); PTC Therapeutics, Inc. (Director · Since at least Jun 19, 2013); NexImmune, Inc. (Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Sorrento Therapeutics, Inc. (See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past) | Board Director · Since at least Jun 22, 2011 |
| Anthony Gregg Lapointe Other companies: Astria Therapeutics Inc (Director · Since at least Jan 3, 2019); Rigel Pharmaceuticals, Inc. (Director · Since at least Oct 31, 2017); Raptor Pharmaceutical Corp (Director · Jan 1, 2015 – Oct 24, 2016 · Past); Questcor Pharmaceuticals Inc (Director · Oct 9, 2009 – Jan 1, 2010 · Past); SciClone Pharmaceuticals Inc (Director · Mar 30, 2009 – Oct 13, 2017 · Past) | Director · Since at least Mar 10, 2009 |
| Diane Parks Other companies: Celularity Inc. (Director · Since at least Jun 2, 2022); Kura Oncology, Inc. (Director · Since at least Oct 14, 2019); CTi Biopharma Corp (Director · Aug 24, 2021 – Jun 26, 2023 · Past) | Board Director · Since at least Jul 8, 2019 |
| Keith L Brownlie Other companies: Celldex Therapeutics, Inc. (Director · Since at least Jun 15, 2017); Cancer Genetics Inc (Director · Jul 24, 2013 – May 22, 2014 · Past); Phio Pharmaceuticals Corp. (Director · Mar 1, 2013 – Feb 13, 2019 · Past) | Director · Jun 21, 2012 – Sep 27, 2018 · Past |
| Michael Sember Other companies: Quoin Pharmaceuticals. Ltd (Director · Since at least Jan 1, 2023); Iomed Inc (Director · Nov 9, 2006 – Aug 9, 2007 · Past) | Chief Executive Officer, Director · Apr 10, 2006 – Apr 10, 2006 · Past |
| Gregg A. Lapointe Other companies: Rigel Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026) | Board Director · Since at least Nov 5, 2026 |
| James S Kuo Other companies: Theriva Biologics, Inc. (Chairman, CEO & President, Director · Dec 22, 2009 – Aug 30, 2011 · Past) | Director · Jun 4, 2009 – Jun 4, 2009 · Past |
| Karen R Krumeich Other companies: Aksys Ltd (Interim CFO · Sep 18, 2006 – Sep 18, 2006 · Past) | SVP and CFO · Jun 16, 2016 – Dec 13, 2018 · Past |
| Steve H Kanzer Other companies: Theriva Biologics, Inc. (Director · Oct 31, 2006 – Jan 5, 2011 · Past) | Director · Jan 10, 2006 – Feb 9, 2007 · Past |
| Adam T. Rumage | Senior Vice President, Project Management & Regulatory Affairs · Since at least Nov 5, 2026 |
All 19 people
| Person | Seat |
|---|---|
| Christopher J. Schaber | Chairman, President and Chief Executive Officer · Since at least Apr 22, 2019 |
| Cyrille F Buhrman | Director · Jun 28, 2007 – Jun 4, 2009 · Past |
| Jonathan L. Guarino | Senior Vice President and Chief Financial Officer · Since at least Nov 15, 2024 |
| Mark E Pearson | Director · Jul 2, 2018 – Sep 6, 2019 · Past |
| Oreola Donini | Senior Vice President and Chief Scientific Officer · Since at least Dec 11, 2025 |
| Richard Straube | CMO (Consulting) · Since at least Jan 6, 2014 |
| Robert J. Rubin | Board Director · Since at least Jun 16, 2016 |
| Robert N Brey | Chief Scientific Off., Sr. VP · Mar 27, 2009 – Dec 5, 2013 · Past |
| Timothy R Cote | Director · May 3, 2023 – May 3, 2023 · Past |
Log in to ask 6ix AI your own questions about Soligenix, Inc.